FI3463457T3 - Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa - Google Patents
Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa Download PDFInfo
- Publication number
- FI3463457T3 FI3463457T3 FIEP17730627.1T FI17730627T FI3463457T3 FI 3463457 T3 FI3463457 T3 FI 3463457T3 FI 17730627 T FI17730627 T FI 17730627T FI 3463457 T3 FI3463457 T3 FI 3463457T3
- Authority
- FI
- Finland
- Prior art keywords
- nivolumab
- dose
- subject
- lymphoma
- administered
- Prior art date
Links
- 229960003301 nivolumab Drugs 0.000 title claims 6
- 208000017604 Hodgkin disease Diseases 0.000 title claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 title claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 title claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 3
- 229960003901 dacarbazine Drugs 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 229960003048 vinblastine Drugs 0.000 claims 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 3
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344880P | 2016-06-02 | 2016-06-02 | |
| PCT/US2017/035492 WO2017210453A1 (en) | 2016-06-02 | 2017-06-01 | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3463457T3 true FI3463457T3 (fi) | 2023-09-12 |
Family
ID=59067911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17730627.1T FI3463457T3 (fi) | 2016-06-02 | 2017-06-01 | Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11083790B2 (pl) |
| EP (2) | EP3463457B1 (pl) |
| JP (3) | JP7175198B2 (pl) |
| KR (2) | KR20230038318A (pl) |
| CN (1) | CN109475633A (pl) |
| DK (1) | DK3463457T3 (pl) |
| ES (1) | ES2954139T3 (pl) |
| FI (1) | FI3463457T3 (pl) |
| HR (1) | HRP20230864T1 (pl) |
| HU (1) | HUE062398T2 (pl) |
| LT (1) | LT3463457T (pl) |
| PL (1) | PL3463457T3 (pl) |
| PT (1) | PT3463457T (pl) |
| RS (1) | RS64388B1 (pl) |
| SI (1) | SI3463457T1 (pl) |
| SM (1) | SMT202300290T1 (pl) |
| WO (1) | WO2017210453A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| EP4458417A3 (en) | 2015-08-11 | 2025-02-19 | Wuxi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| PL3464368T3 (pl) | 2016-06-02 | 2023-08-28 | Bristol-Myers Squibb Company | Zastosowanie przeciwciała anty-pd-1 w skojarzeniu z przeciwciałem anty-cd30 w leczeniu chłoniaka |
| PL3463457T3 (pl) | 2016-06-02 | 2023-08-21 | Bristol-Myers Squibb Company | Blokada pd-1 niwolumabem w opornym chłoniaku hodgkina |
| JP2021510697A (ja) | 2018-01-12 | 2021-04-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | がん処置のための坑ｉｌ−８抗体及び坑ｐｄ−１抗体を用いる組合せ治療 |
| KR20200119845A (ko) * | 2018-02-13 | 2020-10-20 | 머크 샤프 앤드 돔 코포레이션 | 항 pd-1 항체 및 항 ctla4 항체를 사용한 암의 치료 방법 |
| WO2020135415A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| KR20210146348A (ko) * | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2025136845A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Methods of treating a patient with a pd-1 antagonist |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| HU228477B1 (en) | 1999-08-23 | 2013-03-28 | Dana Farber Cancer Inst Inc | Pd-1, a receptor for b7-4, and uses therefor |
| CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20060032289A1 (en) | 2004-08-11 | 2006-02-16 | Pinnaduwage Lal A | Non-optical explosive sensor based on two-track piezoresistive microcantilever |
| MX2007013978A (es) | 2005-05-09 | 2008-02-22 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos. |
| CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| KR101562580B1 (ko) | 2007-06-18 | 2015-10-22 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
| BRPI0917592B1 (pt) | 2008-12-09 | 2021-08-17 | Genentech, Inc | Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição |
| RS60033B1 (sr) | 2009-11-24 | 2020-04-30 | Medimmune Ltd | Ciljano vezujući agensi usmereni na b7-h1 |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| MX360254B (es) | 2011-03-10 | 2018-10-26 | Pfizer | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. |
| WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| CA3213528A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CN109513003A (zh) * | 2012-08-14 | 2019-03-26 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| WO2015035606A1 (en) | 2013-09-13 | 2015-03-19 | Beigene, Ltd. | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| SG10201913297TA (en) | 2015-03-13 | 2020-02-27 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| PL3463457T3 (pl) | 2016-06-02 | 2023-08-21 | Bristol-Myers Squibb Company | Blokada pd-1 niwolumabem w opornym chłoniaku hodgkina |
-
2017
- 2017-06-01 PL PL17730627.1T patent/PL3463457T3/pl unknown
- 2017-06-01 CN CN201780047962.4A patent/CN109475633A/zh active Pending
- 2017-06-01 SI SI201731382T patent/SI3463457T1/sl unknown
- 2017-06-01 KR KR1020237008131A patent/KR20230038318A/ko not_active Ceased
- 2017-06-01 ES ES17730627T patent/ES2954139T3/es active Active
- 2017-06-01 RS RS20230598A patent/RS64388B1/sr unknown
- 2017-06-01 HR HRP20230864TT patent/HRP20230864T1/hr unknown
- 2017-06-01 DK DK17730627.1T patent/DK3463457T3/da active
- 2017-06-01 US US16/306,285 patent/US11083790B2/en active Active
- 2017-06-01 SM SM20230290T patent/SMT202300290T1/it unknown
- 2017-06-01 PT PT177306271T patent/PT3463457T/pt unknown
- 2017-06-01 KR KR1020187037835A patent/KR20190015377A/ko not_active Ceased
- 2017-06-01 JP JP2018563008A patent/JP7175198B2/ja active Active
- 2017-06-01 WO PCT/US2017/035492 patent/WO2017210453A1/en not_active Ceased
- 2017-06-01 HU HUE17730627A patent/HUE062398T2/hu unknown
- 2017-06-01 EP EP17730627.1A patent/EP3463457B1/en active Active
- 2017-06-01 FI FIEP17730627.1T patent/FI3463457T3/fi active
- 2017-06-01 EP EP23174335.2A patent/EP4248990A3/en active Pending
- 2017-06-01 LT LTEPPCT/US2017/035492T patent/LT3463457T/lt unknown
-
2021
- 2021-08-09 US US17/397,221 patent/US20220025049A1/en not_active Abandoned
-
2022
- 2022-11-08 JP JP2022178836A patent/JP7568698B2/ja active Active
-
2024
- 2024-10-02 US US18/905,043 patent/US20250134996A1/en active Pending
- 2024-10-03 JP JP2024174007A patent/JP2025020119A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109475633A (zh) | 2019-03-15 |
| US11083790B2 (en) | 2021-08-10 |
| JP2025020119A (ja) | 2025-02-12 |
| DK3463457T3 (da) | 2023-10-02 |
| SI3463457T1 (sl) | 2023-09-29 |
| HRP20230864T1 (hr) | 2023-11-10 |
| EP3463457B1 (en) | 2023-06-28 |
| JP2019517504A (ja) | 2019-06-24 |
| HUE062398T2 (hu) | 2023-10-28 |
| US20220025049A1 (en) | 2022-01-27 |
| WO2017210453A1 (en) | 2017-12-07 |
| EP4248990A2 (en) | 2023-09-27 |
| PT3463457T (pt) | 2023-09-07 |
| KR20190015377A (ko) | 2019-02-13 |
| PL3463457T3 (pl) | 2023-08-21 |
| ES2954139T3 (es) | 2023-11-20 |
| LT3463457T (lt) | 2023-09-11 |
| RS64388B1 (sr) | 2023-08-31 |
| KR20230038318A (ko) | 2023-03-17 |
| EP4248990A3 (en) | 2024-01-03 |
| EP3463457A1 (en) | 2019-04-10 |
| JP7568698B2 (ja) | 2024-10-16 |
| JP7175198B2 (ja) | 2022-11-18 |
| JP2023025012A (ja) | 2023-02-21 |
| US20250134996A1 (en) | 2025-05-01 |
| SMT202300290T1 (it) | 2023-11-13 |
| US20190290757A1 (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3463457T3 (fi) | Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa | |
| MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| CA2956871C (en) | Compounds active towards bromodomains | |
| PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| WO2015195848A8 (en) | Ezh2 inhibitors for treating lymphoma | |
| MY205639A (en) | Fgfr/pd-1 combination therapy for the treatment of cancer | |
| WO2016044189A8 (en) | Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists | |
| EA201790951A1 (ru) | Производные гидроксиалкилзамещенного фенилтриазола и их применение | |
| WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| FI3464368T3 (fi) | Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| WO2015187998A3 (en) | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy | |
| WO2016207090A3 (en) | Targeted conjugates of ksp inhibitors | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| AR116121A1 (es) | Métodos de tratamiento del cáncer | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| MX2017005350A (es) | Terapia para la inhibicion de la replicacion del virus de arn monocatenario. | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| WO2016100738A3 (en) | Antifibrotic activity of gas6 inhibitor | |
| FI3270909T3 (fi) | Etc1002:ta ja yhtä tai useampaa statiinia käsittäviä kiinteäannoksisia yhdistelmiä kardiovaskulaarisen riskin hoitoon tai ehkäisemiseen | |
| HK1258276A1 (zh) | 用於治疗hiv的化合物和组合 | |
| CA3010788A1 (en) | Methods of administering vasopressors | |
| WO2018102261A3 (en) | Boronic derivatives hydroxamates as anticancer agents | |
| EA201791953A1 (ru) | Новые способы лечения рака | |
| SG11201901617PA (en) | Azole compound ophthalmic preparation |